### Edgar Filing: Webster Stephen W - Form 4

Webster Stej Form 4	-											
November 2											PROVAL	
FORM	<b>ORM 4</b> UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMMISSION	OMB OMB Number:	3235-0287		
Check th if no long subject to Section 1 Form 4 of Form 5 obligatio may com <i>See</i> Instr 1(b).	ger ST o ST 16. or Fi ons Sect tinue.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section									Expires:January 31, 2005Estimated average burden hours per response0.5	
(Print or Type ]	Responses)											
1. Name and Address of Reporting Person <u>*</u> Webster Stephen W			2. Issuer Name <b>and</b> Ticker or Trading Symbol Spark Therapeutics, Inc. [ONCE]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) C/O SPARI INC., 3737 SUITE 1300	MARKET	PEUTI		3. Date of (Month/E 11/16/2	•	ransaction			Director X Officer (give below)	10%	Owner er (specify	
	(Street)				endment, Da hth/Day/Year	-	l		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
PHILADEL	LPHIA, PA	A 19104							Form filed by M Person	ore than One Re	porting	
(City)	(State)		(Zip)	Tabl	le I - Non-I	Derivative	Securi	ities Acqu	iired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	ecurity (Month/Day/Year) Executio Instr. 3) any		ned n Date, if Day/Year)	4. Securit on(A) or Di (Instr. 3, 4	sposed	l of (D)	BeneficiallyForm:Owned(D) orFollowingIndireReported(Instructions)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common	11/16/20	)17			Code V M	Amount 10,000	(D)	Price	(Instr. 3 and 4) 12,500	D		
Stock	11/10/20	/1/			141	10,000	11		12,500	D		
Common Stock	11/16/20	017			S <u>(1)</u>	10,000	D	\$ 70.14	2,500	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Edgar Filing: Webster Stephen W - Form 4

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day/	ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 I S (
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 3.45	11/16/2017		М	10,000	(3)	07/07/2024	Common Stock	10,000	

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
1 0	Director	10% Owner	Officer	Other		
Webster Stephen W C/O SPARK THERAPEUTICS, INC. 3737 MARKET STREET, SUITE 1300 PHILADELPHIA, PA 19104			Chief Financial Officer			
Signatures						
/s/ Joseph W. La Barge, attorney-in-fact for S Webster	tephen	11/	20/2017			
**Signature of Reporting Person			Date			

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2017, as amended.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$70.00 to \$70.95, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics,

- (2) In start of the reporting person undertakes to provide to spark interapedites, inc., any security holder of spark interapedites, inc., any security holder of spark interapedites, inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- (3) This option was granted on July 7, 2014 and vests over four years, with 25% of the shares underlying the option vesting on July 7, 2015, and the remainder vesting quarterly thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.